BeStock  
Stocks › Biotechnology › RIGL

Rigel Pharmaceuticals RIGL

US equityMarket cap rank #3311Biotechnology
$47.99 +$1.88 (+4.08%)
Pre-market · Oct 8, 8:40 am ET · After hours $47.00 -2.06%
Open$45.64
Prev close$46.11
Day range$45.22 – $48.15
Volume232.6K
Market cap$896.45M
P/E (TTM)2.8
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership90.9%-2.31 pts vs. prior quarter
Institutions holding201-4 vs. prior quarter
Insider trades (recent)26 buys / 22 sellsNet buying
Short interest17.09% of floatDays to cover 15.8 · as of 15 Sep 2026
Short-sale volume share23.9%5-day average of daily volume

Short-sale volume as % of daily volume

18%25%32%38%Sep '26Sep '26Oct '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$2.75M (7 inflow days, 13 outflow days).

Net flow by order size, last 20 sessions

−$2.9MSuper+$186.9KBig+$317.2KMid−$771.6KSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 39.6% of shares outstanding.

Largest holders

  • BlackRock10.38%
  • Soleus Capital Management, L.P.9.87%
  • Armistice Capital LLC8.95%
  • State Street Global Advisors5.57%
  • Vanguard Capital Management, LLC4.85%
  • American Century Investment Management3.97%
  • LSV Asset Management3.86%
  • Acadian Asset Management LLC3.17%

By investor type

  • Mutual Fund55.27%
  • Hedge Fund30.00%
  • Public Company3.03%
  • Individual/Insider1.74%
  • Government Pension Fund0.73%
  • Bank/Investment Bank0.62%
  • Family Office/Trust0.56%
  • Private Company0.36%

Reported short interest has fallen from 17.58% to 17.09% of float over the last 6 biweekly reports (30 Jun 2026 to 15 Sep 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
Soleus Capital Management, L.P. Hedge Fund 2026/Q3 +1,833,504 9.9%
Armistice Capital LLC Hedge Fund 2026/Q3 +392,000 9.0%
American Century Investment Management Mutual Fund 2026/Q3 +197,287 4.0%
Macquarie Investment Management Business Trust Mutual Fund 2026/Q3 +195,000 1.0%
Bridgeway Capital Management, LLC Mutual Fund 2026/Q3 +190,848 1.1%
BlackRock Mutual Fund 2026/Q3 +170,911 10.4%
LSV Asset Management Mutual Fund 2026/Q3 +120,159 3.9%
Centerbook Partners LP Hedge Fund 2026/Q3 +109,575 0.6%
D. E. Shaw & Co., L.P. Hedge Fund 2026/Q3 +96,861 2.9%
Morgan Stanley Public Company 2026/Q3 +87,904 0.8%
Vanguard Portfolio Management, LLC Mutual Fund 2026/Q3 +86,193 1.3%
UBS Asset Management Mutual Fund 2026/Q3 +72,878 0.7%
Lionhunter Capital Management, LLC Family Office/Trust 2026/Q3 +63,045 0.3%
Geode Capital Management, LLC Mutual Fund 2026/Q3 +42,549 2.6%
Squarepoint OPS LLC Hedge Fund 2026/Q3 +38,550 0.4%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
1 Sep 2026 Dean Schorno Chief Financial Officer Derivative Exercise and Retained +4,600 $24.20 44,079
31 Aug 2026 Raul Rodriguez Chief Executive Officer Sale to Issuer -2,424 $47.50 179,400
31 Aug 2026 Dean Schorno Chief Financial Officer Sale to Issuer -928 $47.50 44,079
31 Aug 2026 Raymond Furey General Counsel Sale to Issuer -877 $47.50 14,201
31 Aug 2026 David Santos Executive Vice President Sale to Issuer -874 $47.50 23,320
7 Jul 2026 Alison Hannah Independent Director Other Acquisition +24,400 – 24,400
21 Jun 2026 Kamil Jackson Independent Director Automatic Disposition -2,500 $35.00 10,125
16 Jun 2026 Raul Rodriguez Chief Executive Officer Other Derivative Acquisition +31,700 $22.49 31,700
16 Jun 2026 Lisa Rojkjaer Chief Medical Officer Other Derivative Acquisition +16,769 $22.49 7,394
16 Jun 2026 Dean Schorno Chief Financial Officer Other Derivative Acquisition +7,394 $22.49 7,394
16 Jun 2026 Raymond Furey General Counsel Other Derivative Acquisition +7,394 $22.49 7,394
16 Jun 2026 David Santos Executive Vice President Other Derivative Acquisition +7,394 $22.49 7,394
31 May 2026 Raul Rodriguez Chief Executive Officer Sale to Issuer -2,424 $29.86 181,138
31 May 2026 Lisa Rojkjaer Chief Medical Officer Sale to Issuer -850 $29.86 3,539
31 May 2026 Dean Schorno Chief Financial Officer Derivative Exercise and Sale -928 $29.86 38,187
31 May 2026 Dean Schorno Chief Financial Officer Derivative Exercise and Retained +2,453 $18.70 38,187
31 May 2026 Raymond Furey General Counsel Sale to Issuer -877 $29.86 12,952
31 May 2026 David Santos Executive Vice President Sale to Issuer -874 $29.86 22,074
25 May 2026 Kamil Jackson Independent Director Automatic Disposition -2,500 $29.17 6,875
14 May 2026 Walter Moos Independent Director Other Acquisition +5,750 – 5,750

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
15 Sep 2026 3,191,811 17.1% 15.8
31 Aug 2026 3,182,110 17.0% 9.1
14 Aug 2026 3,203,364 17.1% 9.8
31 Jul 2026 3,092,899 16.7% 10.6
15 Jul 2026 3,157,453 17.1% 7.9
30 Jun 2026 3,252,727 17.6% 7.2

Discussion

No comments yet — be the first to weigh in on RIGL.

Leave a comment

Scroll to Top